Vanda Pharmaceuticals Inc
Insys Therapeutics: Recommendations and Market Capitalization
Wall Street analysts estimate that INSY stock could decrease ~3% over the next 12 months. That show a 12-month target price of $9.60.
Analysts’ Ratings for Alkermes and Its Peers in February 2018
Of the 12 analysts covering Alkermes (ALKS) in February, five analysts gave ALKS a “buy” rating. Seven analysts gave it a “hold” rating.
What Investors Can Expect from Vanda Pharmaceuticals in 2018
Investors can expect a slew of critical developments from Vanda Pharmaceuticals (VNDA) in 2018.
A Look at Vanda Pharmaceuticals’ Product Portfolio
Vanda Pharmaceuticals’ (VNDA) Hetlioz was approved by the FDA in January 2014 for the treatment of Non-24-Hour Sleep Wake Disorder.
Analyst Ratings for Vanda Pharmaceuticals and Peers in February
Of the six analysts covering Vanda Pharmaceuticals in February 2018, two of them have given the stock a “strong buy” rating.